Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunogen Inc (NQ: IMGN ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Immunogen Inc < Previous 1 2 3 4 5 Next > ImmunoGen Inc. (NASDAQ: IMGN) Near Top of Volume Charts in Thursday Trading February 08, 2024 Via Investor Brand Network ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 01, 2024 From ImmunoGen, Inc. Via Business Wire Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate January 29, 2024 Via Get News Exposures Product Safety Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate January 29, 2024 New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug... Via TheNewswire.com Exposures Product Safety ImmunoGen Inc. (NASDAQ: IMGN) Near Top of Volume Charts in Thursday Trading November 30, 2023 Via Investor Brand Network ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 03, 2024 From ImmunoGen, Inc. Via Business Wire Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals December 29, 2023 Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. Via MarketBeat AbbVie continues shopping spree with biotech buyout December 12, 2023 While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend. Via MarketBeat BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. December 11, 2023 From Brodsky & Smith LLC Via GlobeNewswire ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH December 10, 2023 From ImmunoGen Inc. Via Business Wire FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer December 05, 2023 From ImmunoGen, Inc. Via Business Wire IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN December 04, 2023 From Kahn Swick & Foti, LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR) December 04, 2023 From Brodsky & Smith LLC Via GlobeNewswire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 01, 2023 From ImmunoGen, Inc. Via Business Wire IMGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ImmunoGen, Inc. Is Fair to Shareholders November 30, 2023 From Halper Sadeh LLC Via Business Wire ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference November 02, 2023 From ImmunoGen, Inc. Via Business Wire ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results November 02, 2023 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 01, 2023 From ImmunoGen, Inc., Via Business Wire ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer October 27, 2023 From ImmunoGen, Inc. Via Business Wire ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results October 19, 2023 From ImmunoGen Inc. Via Business Wire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 29, 2023 From ImmunoGen, Inc. Via Business Wire ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer September 28, 2023 From ImmunoGen Inc. Via Business Wire On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope September 20, 2023 FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress... Via FinancialNewsMedia ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 18, 2023 From ImmunoGen, Inc. Via Business Wire ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer September 18, 2023 From ImmunoGen, Inc. Via Business Wire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 05, 2023 From ImmunoGen, Inc. Via Business Wire ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan August 28, 2023 From ImmunoGen, Inc. Via Business Wire ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 01, 2023 From ImmunoGen, Inc. Via Business Wire ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer July 31, 2023 From ImmunoGen, Inc. Via Business Wire ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results July 31, 2023 From ImmunoGen, Inc. Via Business Wire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.